Novel antitoxin and vaccine platform based on nodavirus VLPS
AssigneesThe Salk Institute for Biological Studies, The Scripps Research Institute
InventorsJohn Young, Anette Schneemann, Marianne Manchester, Kelly Dryden, John M. Marlett, Darly Joseph Manayani, Godfrey Jonah Anderson Rainey, Vijay Reddy, Marc E. Siladi, Heather M. Scobie, Diane Thomas, Mark Yeager
Life of this patent
Estimating the term…
Abstract
Antitoxin and vaccine compositions based on nodavirus VLPs are provided. Anthrax antitoxin and vaccine compositions are provided. Methods of treating toxins with VLP-based antitoxins are provided. Methods of raising an immune response with immunogen decorated VLPs are provided.
Claims29
An antitoxin comprising a nodavirus-derived virus like particle (VLP) that displays a heterologous toxin binding domain.
(canceled)
8-9. (canceled)
An immunogenic composition comprising a nodavirus-derived virus like particle (VLP) that comprises a heterologous immunogen binding domain, which binding domain is bound to a first heterologous immunogen.
(canceled)
17-18. (canceled)
The immunogenic composition of claim 18, wherein the first domain of the first and second heterologous immunogen comprises a domain derived from PA, and the second domain of the first heterologous immunogen comprises a domain derived from botulinum A toxin and the second domain of the second heterologous immunogen comprises a domain derived from ricin toxin.
An immunogenic composition comprising a nodavirus-derived virus like particle (VLP) comprising a heterologous immunogen derived from an anthrax toxin.
21-23. (canceled)
An immunogenic composition, comprising:
- a viral nanoparticle derived from a nodavirus, which viral nanoparticle comprises a heterologous immunogen binding domain;
- wherein the viral nanoparticle is decorated with at least one immunogen, wherein the immunogen comprises a first domain that is bound by the heterologous immunogen binding domain, and a second domain that is heterologous to the first domain.
25-35. (canceled)
A method of antitoxin therapy to treat a toxin in a patient, the method comprising:
- identifying a patient in need of antitoxin therapy;
- and,
- administering to the patient an antitoxin that comprises a nodavirus-derived virus like particle (VLP) that comprises a heterologous toxin binding domain;
- wherein the binding domain binds the toxin in the patient, thereby acting as an antitoxin.
37-42. (canceled)
A method of vaccinating a patient with an immunogen decorated nodavirus derived VLP, the method comprising:
- binding an immunogen to an immunogen binding site displayed on the VLP;
- and,
- administering the resulting immunogen decorated VLP to a patient, thereby vaccinating the patient against the immunogen.
44-50. (canceled)
A method of vaccinating a patient against anthrax infection, the method comprising:
- providing a composition comprising a nodavirus-derived VLP that comprises or is decorated with an anthrax-derived immunogen;
- and,
- administering the composition to a patient, thereby vaccinating the patient against the anthrax-derived immunogen.
52-56. (canceled)
A method of vaccinating a patient against infection, the method comprising:
- providing a composition comprising a nodavirus-derived VLP that comprises an immunogen binding site recombinantly expressed as part of the VLP, wherein the immunogen binding site is bound to an immunogen, wherein the immunogen comprises a first domain that is bound by the binding domain and a second domain that is heterologous to the first domain;
- and,
- administering the composition to a patient, thereby vaccinating the patient against the immunogen.
58-61. (canceled)
Dependencies are inferred from the claim text.